Nebu-Flow: Transforming Respiratory Drug Delivery
Respiratory diseases like asthma, COPD, and cystic fibrosis remain leading global health challenges, costing billions annually. In the UK alone, 10,000 new diagnoses occur each week, placing immense strain on healthcare systems.
The Vision
Traditional nebulisers waste medication and struggle with effective lung delivery. Enter Nebu-Flow, developed by Dr. Elijah Nazarzadeh and Professor Jonathan Cooper at the University of Glasgow. This breakthrough nebuliser, commercialized by Acu-Flow Limited, harnesses Surface Acoustic Wave (SAW) technology to create ultra-fine drug particles, ensuring deeper, more effective lung penetration.
Development and features
60% increase in aerosol inhalation
Nebu-Flow performance has shown an impressive increase in the aerosol inhalable fraction of drugs, of up to 60% improvement, when compared with current, best-in-class products.
Optimised bench-top device
Transitioned from lab prototype to optimised bench-top device.
Portable and hand-held
Next stage is developing a portable, hand-held model for real-world use.
Support from the College of Medical, Veterinary & Life Sciences (MVLS)
The College of Medical, Veterinary & Life Sciences (MVLS) has been instrumental in supporting Nebu-Flow. MVLS provided essential resources and funding through various initiatives, including the Translational Research Initiative (TRI). This support enabled the team to conduct preliminary translational work and progress their technology to the next stage of commercialisation.
The validation of the technology and engagement with leading companies in the field allowed the platform to be tested against industry standards and characterisation requirements. They were also able to present their findings at conferences and exhibitions, engaging widely with industry, confirming the requirements for new nebulisers, their competitive edge and the route to market. These crucial steps to their success enabled real world validation of Nebu-Flow technology.
Impact and achievements
Nebu-Flow’s impact has earned it significant accolades:
- Innovate UK-funded ICURe and RSE Unlocking Ambition Fellowship
- The Higgs Prize (Scottish Edge Competition)
- Institute of Physics Lee Lucas Business Start-Up Award
- £1.7M investment round to drive mass production and distribution
- £4.7M investment in 2024
Future prospects
Nebu-Flow is on track to redefine respiratory treatment. With strong industry backing and continuous innovation, the next step is scaling manufacturing and securing regulatory approvals. The future of inhalation therapy is here—and it’s more precise, efficient, and accessible than ever.
Explore More About Advanced Diagnostics and Therapeutics
Advanced Diagnostics and Therapeutics aims to pioneer development and delivery of the next generation of novel human and animal clinical interventions.